BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18197807)

  • 1. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.
    Arlen PM; Gulley JL; Madan RA; Hodge JW; Schlom J
    Crit Rev Immunol; 2007; 27(5):451-62. PubMed ID: 18197807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costimulatory molecules as adjuvants for immunotherapy.
    Hodge JW; Greiner JW; Tsang KY; Sabzevari H; Kudo-Saito C; Grosenbach DW; Gulley JL; Arlen PM; Marshall JL; Panicali D; Schlom J
    Front Biosci; 2006 Jan; 11():788-803. PubMed ID: 16146771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
    Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
    Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
    Kudo-Saito C; Schlom J; Hodge JW
    Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
    Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
    Arlen P; Tsang KY; Marshall JL; Chen A; Steinberg SM; Poole D; Hand PH; Schlom J; Hamilton JM
    Cancer Immunol Immunother; 2000 Dec; 49(10):517-29. PubMed ID: 11129322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
    Hodge JW; Higgins J; Schlom J
    Vaccine; 2009 Jul; 27(33):4475-82. PubMed ID: 19450631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines.
    Schlom J; Sabzevari H; Grosenbach DW; Hodge JW
    Artif Cells Blood Substit Immobil Biotechnol; 2003 May; 31(2):193-228. PubMed ID: 12751840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
    Gulley JL; Arlen PM; Tsang KY; Yokokawa J; Palena C; Poole DJ; Remondo C; Cereda V; Jones JL; Pazdur MP; Higgins JP; Hodge JW; Steinberg SM; Kotz H; Dahut WL; Schlom J
    Clin Cancer Res; 2008 May; 14(10):3060-9. PubMed ID: 18483372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
    Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
    Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A triad of costimulatory molecules synergize to amplify T-cell activation.
    Hodge JW; Sabzevari H; Yafal AG; Gritz L; Lorenz MG; Schlom J
    Cancer Res; 1999 Nov; 59(22):5800-7. PubMed ID: 10582702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
    Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
    J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3).
    Shankar P; Schlom J; Hodge JW
    Vaccine; 2001 Dec; 20(5-6):744-55. PubMed ID: 11738738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRICOM vector based cancer vaccines.
    Garnett CT; Greiner JW; Tsang KY; Kudo-Saito C; Grosenbach DW; Chakraborty M; Gulley JL; Arlen PM; Schlom J; Hodge JW
    Curr Pharm Des; 2006; 12(3):351-61. PubMed ID: 16454749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations.
    Boehm AL; Higgins J; Franzusoff A; Schlom J; Hodge JW
    Cancer Immunol Immunother; 2010 Mar; 59(3):397-408. PubMed ID: 19756595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules.
    Kudo-Saito C; Schlom J; Hodge JW
    Clin Cancer Res; 2004 Feb; 10(3):1090-9. PubMed ID: 14871989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules.
    Hodge JW; Rad AN; Grosenbach DW; Sabzevari H; Yafal AG; Gritz L; Schlom J
    J Natl Cancer Inst; 2000 Aug; 92(15):1228-39. PubMed ID: 10922408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity.
    Hodge JW; Grosenbach DW; Schlom J
    Cancer Detect Prev; 2002; 26(4):275-91. PubMed ID: 12430632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.